MethodSense Announces Growth Plans to Meet the Demands of a Rapidly Evolving Regulatory Landscape
-
MethodSense Announces Growth Plans to Meet the Demands of a Rapidly Evolving Regulatory Landscape
With new leadership, platform innovation, and an AI-era focus, MethodSense is scaling its service offerings and software platform to help MedTech innovators meet global regulatory demands. Morrisville, NC – July 23, 2025, MethodSense, a leading regulatory and quality consulting firm for the life sciences industry, today announced a bold new phase of growth, propelled by…
-
MethodSense Launches Elsa & AI Resource Center to Help Medical Device Companies Navigate the FDA’s AI Era
Morrisville, NC – July 11, 2025, MethodSense, a regulatory consulting and technology firm with more than 25 years of experience guiding medical device companies through the FDA and onto commercial markets, today announced the launch of its Elsa & AI Resource Center at MethodSense.com. This new resource hub provides critical guidance, tools, and expert insights…
-
The FDA Just Went AI. Are You Ready?
Elsa Signals the Start of the FDA’s AI Era. Here’s What It Means for YouBy Rita King, CEO, MethodSense The FDA just dropped a game-changer: Elsa, its new generative AI tool. And it’s already transforming how medical device companies are evaluated and regulated. Elsa is actively supporting FDA reviews. At MethodSense, we have already seen…